Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Amphiregulin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Amphiregulin Mature Form Recombinant Protein (UniProt P15514, Cys104-Val221). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. | View Amphiregulin Products |
| Gene Delivery | Amphiregulin Promise-ORF / Lentivirus. Full-length ORF with native signal peptide for secreted expression and stable cell line generation. | View Amphiregulin Products |
| Benchmark Ab | Anti-Amphiregulin Neutralizing Antibody. Recombinant positive control for blocking AREG-EGFR interaction. | View Amphiregulin Products |
| Validator | Amphiregulin siRNA Set. For knockdown verification and specificity controls in functional cell assays. | View Amphiregulin Products |
| Receptor Partner | EGFR (ERBB1). Primary receptor for AREG binding assays and competition studies. | View EGFR Products |
| Related Ligand – Epiregulin | Epiregulin (EREG). Competing EGFR ligand for selectivity profiling and pan-ligand comparison. | View Epiregulin Products |
| Protease Sheddase – ADAM17 | ADAM17 (TACE). Protease responsible for cleaving pro-AREG to release the mature active form. | View ADAM17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species (cyno/mouse/human) evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence verified. |
| Glycosylation-dependent receptor binding | HEK293 expressed antigens preserve native mammalian glycosylation patterns for accurate SPR/BLI kinetics. |
| EGFR ligand selectivity screening | Homolog panel (AREG, EGF, TGF-α, BTC, EREG, HB-EGF) strictly verified by mass spec for counter-screening. |
| Lack of controls in functional assays | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False positives in target validation | Validated siRNA included for specificity checks and background reduction. |
Live Amphiregulin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Amphiregulin therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum EGFR inhibition to ligand-specific neutralization strategies. Resistance mechanisms to first-generation EGFR inhibitors (cetuximab, panitumumab) in colorectal and lung cancers are increasingly attributed to AREG autocrine loops. The next wave of R&D targets selective AREG blockade to restore EGFR inhibitor sensitivity, while also reducing dose-limiting skin toxicities seen with pan-EGFR approaches. Emerging indications in idiopathic pulmonary fibrosis (IPF) and wound healing disorders position AREG as a dual-track target in oncology and immunology. The selective blockade of AREG-EGFR axis is gaining traction in solid tumors with rich tumor microenvironments and in fibrotic diseases, aiming to halt disease progression while preserving physiological EGFR functions mediated by other ligands.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Antibody (mAb) | Oncology Biotechs, Big Pharma | Colorectal Cancer (EGFRi Resistance), Solid Tumors | Competitive Binding Assay (Need high-purity AREG vs EGFR) |
| Bispecific Antibody | Next-Gen Immuno-Oncology Firms | Refractory Cancers (CRC, NSCLC) | Heterodimer Validation (Need precise ortholog/homolog panel) |
| Decoy Receptor / Trap | Immunology Focused | IPF, Asthma | Soluble Ligand Trapping (Need stable, glycosylated AREG for affinity determination) |
| ADC | Emerging Programs | Solid Tumors (AREG-high) | Internalization Assay (Need AREG-expressing stable cell lines via Lentivirus) |
| Small Molecule (ADAM17 inhibitor) | Targeted Protein Degradation Innovators | Inflammatory Diseases | Shedding Inhibition Assay (Need ADAM17 and precursor AREG models) |
Molecular Differentiation & Assay Strategy
Key differentiation factors for best-in-class drug development
- Affinity: AREG binds EGFR with moderate affinity (Kd ~1-10 nM). Candidate antibodies must achieve sub-nM or pM affinity to outcompete endogenous ligand. True affinity requires natively glycosylated AREG (HEK293 expressed) because glycosylation affects binding kinetics.
- Specificity: The EGF family includes structurally similar ligands (EGF, HB-EGF, TGF-α, Epiregulin). Cross-reactivity can cause severe toxicity. Counter-screening using a full panel of mammalian-expressed ligands is essential.
- Glycosylation sensitivity: Native AREG carries complex N-glycans that influence conformation and stability. Reagents expressed in E. coli lack these modifications and may miss critical epitopes.
Recommended screening assays
- SPR/BLI multi-ligand panel: Simultaneously test binding to AREG, EGF, TGF-α, BTC, HB-EGF, Epiregulin.
- pH-dependent binding kinetics: AREG-EGFR complex dissociation in acidic endosomes affects receptor recycling; test at pH 6.0–7.4.
- Ortholog trio: Use human, cyno, and mouse AREG proteins to confirm cross-species recognition for translational studies.
- Receptor blocking cell assay: Use EGFR-expressing stable cell lines, add candidate drug + recombinant AREG, and measure downstream ERK/AKT phosphorylation.
TarMart’s reagents (HEK293-expressed, sequence verified, >95% purity, endotoxin controlled) directly address all these assay needs, ensuring physiological relevance and data integrity.